Release date: 8 December 2016
Promoter – Financial Intermediary
Acceptable Corporate(s)Location
Description
Capital expenditure investments related to medical technology
Objectives
The project concerns the investment in a new parenteral unit in order to produce large volume parenteral solutions and small volume parenteral solutions.
Sector(s)
- Industry - Manufacturing
Proposed EIB finance (Approximate amount)
EUR 20 million
Total cost (Approximate amount)
EUR 42 million
Environmental aspects
The project falls under Annex II of Environmental Impact Assessment (EIA) Directive 2011/92/EU (implementation of an industrial facility for the production of pharmaceutical products). The project has been screened by the competent authorities and the EIA is currently under public consultation. Full environmental details will be assessed during the appraisal.
Procurement
The promoter is a private company not operating in the utilities sector and is thus not covered by EU directives on procurement.
Status
Signed - 30/06/2017
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).